Advertisement
ARAY vs ILMN
Which Stock Would AI Choose? Accuray (ARAY) vs. Illumina (ILMN) Stock Comparison
Key Takeaways
- Different scale and sector focus: ARAY is a radiation therapy equipment maker, while ILMN is a genomics and DNA-sequencing leader.
- Diverging momentum: Illumina is in a strong uptrend with accelerating revenue growth, while Accuray is managing a revenue decline and a balance-sheet turnaround.
- Profitability gap: Illumina is solidly profitable with expanding margins; Accuray posted a full-year operating loss and did not issue forward guidance.
- Shared China headwind: Both companies cite geopolitical, tariff, and China demand uncertainty as key risks.
- Catalysts differ: Accuray's story centers on restructuring and new partnerships, while Illumina's centers on clinical sequencing adoption.
Introduction
Investors comparing ARAY and ILMN are weighing two very different healthcare-technology profiles. Accuray supplies robotic radiation therapy systems such as CyberKnife, while Illumina dominates DNA sequencing and genomics analysis. This stock comparison is most relevant to traders and investors assessing relative performance and market positioning between a smaller-cap turnaround candidate and a large-cap growth leader. Although both operate in healthcare and share exposure to China-related risks, their business models, momentum, and risk profiles differ sharply, making them a useful contrast for those evaluating where near-term opportunity and longer-term stability currently sit.
ARAY Overview and Recent Performance
Accuray Incorporated (ARAY) develops precision radiation therapy systems, including CyberKnife and Radixact, for oncology and radiosurgery. In recent market activity, the stock has been volatile, reflecting a company navigating both a financial restructuring and softer product demand. For its fiscal 2026, total revenue fell roughly 12% to about $402 million, with product revenue declining sharply as China sales weakened by roughly $58 million amid tariffs and geopolitical uncertainty. The company swung to a full-year operating loss and reported lower adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization).
On the positive side, Accuray exceeded its transformation cost-savings target, strengthened its balance sheet through a transaction with TCW that converted debt into equity and added liquidity, and announced collaborations with Samsung to add imaging capabilities to CyberKnife. Service revenue, a more recurring part of the business, grew modestly. However, management withheld formal fiscal 2027 guidance, and order backlog declined, underscoring limited near-term visibility.
ILMN Overview and Recent Performance
Illumina (ILMN) provides sequencing and array-based technologies used in oncology, reproductive health, life sciences, and emerging genomics applications. Its shares have delivered a strong rally in recent market activity, with a year-to-date gain well above the broader market, driven by robust clinical sequencing demand and improving profitability. In its most recent quarter, revenue rose about 9.5% year over year, and management raised full-year revenue and adjusted EPS (earnings per share) guidance.
Growth has been led by the NovaSeq X platform and expanding clinical applications, with clinical markets representing a majority of sequencing consumables revenue. Illumina also completed the acquisition of SomaLogic, extending into proteomics. The company carries a moderate debt load with healthy liquidity, and continues share repurchases. Key risks include constrained China demand and a valuation that has drawn debate, as some analysts' price targets sit below the current share price after the stock's sharp advance.
Trending AI Robots
For traders looking to systematize decisions like the ARAY versus ILMN comparison, Tickeron's Trending AI Robots page offers a curated view of automated strategies. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, each with its own trading style, timeframe, performance statistics, and basket of securities. Because not every bot suits every market condition, only the strongest and most relevant strategies are featured in the Trending AI Robots section. These bots vary widely in approach, from short-term swing trades to longer-horizon trend-following models, allowing users to explore options aligned with their objectives. Readers interested in AI-driven market analysis can explore the Trending AI Robots page to review the currently featured strategies.
Head-to-Head Comparison
The core contrast between ARAY and ILMN is scale and stage. Illumina generates roughly $4.6 billion in annual revenue with positive earnings and expanding margins, while Accuray generates about $400 million and is working to restore profitability. Their growth drivers also differ: Illumina benefits from rising sequencing intensity and a large installed base that supports recurring consumables, whereas Accuray depends on capital-equipment orders that are more cyclical and exposed to hospital budgeting.
On momentum, Illumina has clear relative strength, while Accuray's trajectory is more uncertain as it digests a restructuring and lacks forward guidance. Risk profiles diverge as well: Illumina's chief risks are China regulation and a potentially stretched valuation, while Accuray faces leverage reduction, thinner margins, and order visibility. Both carry sector exposure to healthcare and to China-related headwinds, but their market sentiment currently reflects opposite phases of the cycle.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue trajectory, and earnings stability, Tickeron's AI would currently lean toward ILMN as the more favorable of the two. Illumina exhibits stronger and more durable upward momentum, positive profitability, and a clearer growth catalyst in clinical sequencing, whereas Accuray's setup is more event-driven and dependent on a still-unfolding turnaround. This assessment is probabilistic rather than definitive: Accuray's partnerships and restructuring could improve its positioning, while Illumina's elevated valuation introduces downside risk. The AI verdict favors the stock with steadier trend signals and stronger fundamentals today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARAY is a Hold and ILMN is a StrongBuy.
ARAY | ILMN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 96 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 31 | |
PRICE GROWTH RATING 1..100 | 63 | 6 | |
P/E GROWTH RATING 1..100 | 33 | 3 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ILMN's Valuation (77) in the Biotechnology industry is in the same range as ARAY (88) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to ARAY’s over the last 12 months.
ILMN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARAY (100) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to ARAY’s over the last 12 months.
ILMN's SMR Rating (31) in the Biotechnology industry is significantly better than the same rating for ARAY (98) in the Medical Specialties industry. This means that ILMN’s stock grew significantly faster than ARAY’s over the last 12 months.
ILMN's Price Growth Rating (6) in the Biotechnology industry is somewhat better than the same rating for ARAY (63) in the Medical Specialties industry. This means that ILMN’s stock grew somewhat faster than ARAY’s over the last 12 months.
ILMN's P/E Growth Rating (3) in the Biotechnology industry is in the same range as ARAY (33) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to ARAY’s over the last 12 months.
| ARAY | ILMN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 69% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 77% |
| Advances ODDS (%) | 16 days ago 73% | 3 days ago 73% |
| Declines ODDS (%) | 2 days ago 85% | 12 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARAY’s FA Score shows that 1 FA rating(s) are green while ILMN’s FA Score has 3 green FA rating(s).
- ARAY’s FA Score: 1 green, 4 red.
- ILMN’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARAY’s TA Score shows that 6 TA indicator(s) are bullish while ILMN’s TA Score has 4 bullish TA indicator(s).
- ARAY’s TA Score: 6 bullish, 4 bearish.
- ILMN’s TA Score: 4 bullish, 4 bearish.
Price Growth
ARAY (@Medical/Nursing Services) experienced а +19.82% price change this week, while ILMN (@Medical Specialties) price change was -2.98% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.19%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was -2.76%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.80%. For the same industry, the average monthly price growth was +3.90%, and the average quarterly price growth was +46.85%.
Reported Earning Dates
ARAY is expected to report earnings on Nov 11, 2026.
ILMN is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.19% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-2.80% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
ARAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARAY has been loosely correlated with ILMN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAY jumps, then ILMN could also see price increases.
| Ticker / NAME | Correlation To ARAY | 1D Price Change % | ||
|---|---|---|---|---|
| ARAY | 100% | -1.07% | ||
| ILMN - ARAY | 41% Loosely correlated | -2.90% | ||
| A - ARAY | 41% Loosely correlated | -3.27% | ||
| ICUI - ARAY | 40% Loosely correlated | -2.07% | ||
| NVST - ARAY | 39% Loosely correlated | -1.32% | ||
| WRBY - ARAY | 38% Loosely correlated | -1.04% | ||
More | ||||